Q-omics provides the consensus-scored ATP5MC1P4 profile across patient tissues and cancer cell-line models. ATP5MC1P4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ATP5MC1P4 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, ATP5MC1P4 RNA expression shows 15,929 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, HNSC, and THYM as cancer lineages where ATP5MC1P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATP5MC1P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATP5MC1P4 survival associations across molecular data types. ATP5MC1P4 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATP5MC1P4 RNA expression–survival associations across cancer types. High ATP5MC1P4 expression shows unfavorable associations in KIRC, ACC, LUAD, LIHC, MESO and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ATP5MC1P4 RNA expression.
This table summarizes ATP5MC1P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ATP5MC1P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATP5MC1P4 shows higher tumor expression in HNSC, BLCA, KIRC, LUSC, STAD and LUAD. The HNSC box plot shows higher ATP5MC1P4 RNA expression in tumor versus normal tissue (log2 FC = +1.415, t-test p < 0.001).
This table shows molecular features associated with ATP5MC1P4 in patient tissues and cancer cell lines. In patient samples, ATP5MC1P4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
